



# EYES CIRCLES, A DELICATE AREA

#### ANATOMICAL AND HISTOLOGICAL LANDMARKS




- ① Fine skin, low level of hyaluronidase
- Supraorbicular fat
- ③ Orbicular muscle
- (4) Suborbital fat (SOOF)
- (5) Periosteum



- O Palpebral line
- 1) Tear trough
- ② Palpebromalar groove
- ③ Medioiugal fold
- (4) Nasolabial fold

#### **(**

#### ANATOMICAL SPECIFICITIES OF THE SUBORBITAL AREA



A complex lymphatic system



High risk areas: (1) Angular artery

② Emergence of the infraorbital nerve V2



# A DIFFERENT GEL DESIGNED TO TREAT EYE CIRCLES FOR A NATURAL AND LONG LASTING CORRECTION

A SOPHISTICATED AND SYNERGISTIC 3-IN-1 FORMULA, COMBINING NATURAL INGREDIENTS

#### SEMI-CROSSLINKED HYALURONIC ACID (HA) 15 mg/g

Mix of cross-linked (1) HA (BDDE) and non cross-linked HA

#### DERMO-RESTRUCTURING COMPLEX (2)

8 amino acids: Glycine, Lysine, Threonine, Proline, Isoleucine, Leucine, Valine, Arginine 3 antioxydants: Glutathion, N-Acetyl-L-cysteine, Alphalipoic acid

2 minerals: Zinc and Copper 1 vitamin: B6



LIDOCAINE

- A SUBTLE BALANCE BETWEEN A LOW LEVEL OF HA
  AND A SEMI-CROSSLINKED HA: A LOW HYGROSCOPIC ACTIVITY
  - To reduce the risk of oedema and swelling with a quantity < 0.5ml by eye circle. (3)
- AN IDEAL VISCOELASTICITY: HIGH SPREADING CAPABILITY
  - To maximise the ease of injection (81%\*) and positioning (100%\*).(3)



Photos: Teoxane data source

- A LIGHT GEL WHICH EXERTS LOW PRESSURE ON THE TISSUES
  - To reduce risk of oedema.(3)

<sup>(1)</sup> From the patented technology RHA: Resilient Hyaluronic  $Acid^{TM}$ 

<sup>(2)</sup> Patent pending technology

<sup>(3)</sup> Phase III multicentric clinical study of 67 patients followed during 1 year (2010)

<sup>\*</sup> Practitioners evaluation



#### SAFETY AND EFFICACY RESULTS - PHASE III STUDY "

#### CLINICAL PROTOCOL

- Multicentric clinical trial held by 6 practitioners with 67 patients
- Follow-up: 1 year
- 5 visits: injection on day 1, check-up at 15 days, 1 month, 3 months, 6 months and 12 months
- GAIS\* cross-evaluation
- No touch-up in 72% of cases. Touch-up only for patients injected with 0.2 ml at first

#### **EFFICIENCY RESULTS**

- PATIENT N° 1
- Indications: tear trough deformity
- Injected volume: 0.15 ml on right side and 0.20 ml on left side
- Slow injection

**BEFORE** 



**AFTER** Immediate result after injection




- PATIENT N° 2
- Indications: tear trough deformity and Palpebromalar groove
- Injected volume: 0.20 ml per side
- Slow injection

**BEFORE** 



**AFTER** Immediate result after injection






#### SAFETY AND EFFICACY RESULTS - PHASE III STUDY (1)

### HIGH DEGREE OF SATISFACTION: PATIENTS AND PRACTITIONERS EVALUATION

Evaluation of the overall aesthetic results by the practitioner and the patient (Percentage of improvement - calculated from the GAIS\*)



The majority of patients were satisfied with the results immediately after injection, at month-6 and month-12 and would recommend it to their relatives. (1)

#### → RECOGNIZED TOLERANCE OVER 1 YEAR

- The safety of Teosyal® PureSense Redensity [II] was demonstrated with an average injected volume of 0.37 ml per eye circle
- Out of 67 patients: 4 cases of transitional side effects were noted. Redness and post-injection bruising disappeared within 72h after injection
  - 1 single case of oedema was observed. The oedema resorbed spontaneously in less than 1 month (0.6ml injected)
  - No tyndall effect was observed



#### **DIAGNOSIS: AN ESSENTIAL STEP**

## APPROPRIATE DIAGNOSIS OF EYE CIRCLES FOR OPTIMAL EFFICACY AND TOLERABILITY

- Sit the patient for diagnosis and evaluation in a semi-reclined position
- Exert a slight pressure on the eye before the injection to help:
  - Determine the orbital margin
  - Detect any lymphatic insufficiency
- Perform a snap test to ensure there is no excessive palpebral looseness

## TEOSYAL® PURESENSE REDENSITY [II] INDICATIONS

- Eye Circles
- Tear trough
- Palpebromalar groove
- Minimal palpebral or malar bags

For malar and jugal area, use more volumising fillers






#### WRONG INDICATIONS

- Exclusively pigmentary dark circles
- Large palpebral or malar bags



Pigmentary dark circles




Large palpebral bags





#### A PRECISE INJECTION TECHNIQUE

#### INJECTION TECHNIQUES

- Slow injection
- Deep supra-periosteal
- Sub-orbicular







Retrograde technique with cannula

#### RECOMMENDED DOSE

Quantity for each eye circle < 0.5ml:</li>

To obtain maximum safety and good long-term results, it is strongly recommended not to inject more than 0.5 ml of Teosyal® PureSense Redensity [II] in each eye circle

#### PROTOCOL

- First session: under correction is recommended
- Touch-up session: 1 month later, only if necessary

#### TEOSYAL® PURESENSE REDENSITY [II]

• Package: 2 x 1ml

CE marking: class III





# TEOSYAL PureSense Redensity [II] 2x1ml TEOXANE GENEVA TEOXANE

Les Charmilles - Rue de Lyon, 105 - CH 1203 Genève Tél. : +41 (0) 22 344 96 36 - Fax : +41 (0) 22 340 29 33

LABORATORIES -

General information: info@teoxane.com

Medical information department: medical@teoxane.com

www.teoxane.com